Animals were immunized twice, two months apart, with the ANRS recombinant MVA-HIV B vaccine (Transgene) at a dose of 4 x 10e8 plaque forming units (PFU) by ID injections distributed over 10 injection points (150 μL/point of injections, all along the back, in two columns). Recombinant HIV-1 antigens consisted of the complete sequence of gag, fused to fragments from pol (residues 172-219, 325-383 and 461-519) and nef (residues 66-147 and 182-206) of the Bru/Lai isolate. Blood samples were taken longitudinally before and after immunizations in either lithium-heparin (Greiner Bio-One) for mass cytometry analysis, or in ethylenediaminetetraacetic acid (EDTA) (Greiner Bio-One) for complete blood counts (CBCs) and plasma preparation. The same batch and dose of vaccine, and vaccine schedule, but a different route of administration, were used relative to a previous preclinical study that analyzed innate responses after SC immunization (9 (link)), and for which the mass cytometry dataset was reused here.
Free full text: Click here